We are pleased to introduce you to Dr. Ivy Gao, CEO of Sunresin, a pioneering company in resin technology for bioprocessing and life sciences. With their recent nomination for CPHI's Women of the Year Award, Ivy shares insights into her leadership journey, Sunresin’s innovative growth strategies, and her vision for a sustainable future in biopharmaceutical manufacturing.

0 0

We are please to share a recent interview with Joerg Ahlgrimm, CEO of SK Pharmteco. In this conversation, Joerg discusses the company's strategic expansion in peptides, their investments across Asia, Europe, and the US, and their recent partnership with Lotte Biologics to advance antibody drug conjugates. He also shares his vision for SK Pharmteco’s growth and leadership in the biotech CDMO space over the next few years.

4 0

Welcome to our exclusive interview with Paolo Paissoni and Dave Short of Procos S.P.A., a leading Contract Development and Manufacturing Organization (CDMO). As the company celebrated its 80th anniversary, we discussed how strategic investments and a commitment to innovation are shaping its future.

Join us as Paolo and Dave share insights into Procos' journey, exploring the significance of their new state-of-the-art R11 facility and their unique approach to customer partnerships.

0 0

3 0

0 0

Exclusive Interview with Riccardo Braglia, Chairman of HAS Healthcare Advanced Synthesis SA

Insights on Strategic Growth & Innovation

In this latest interview, Riccardo Braglia, Chairman of HAS Group, shares valuable insights into the company's latest developments, strategic motivations, and future plans. We discuss the impactful acquisition of Cerbios-Pharma SA, technological advancements, capacity expansions, sustainability initiatives, and the role of 65 Equity Partners.

Don’t miss this comprehensive update on HAS Group’s vision and future trajectory.

1 0

It was a pleasure talking to Zara and learning more about innovation, technologies, digitalization, AI, and much more! Watch this insightful interview to discover more about Lonza.

2 0

1 0